For the year ending 2025-12-31, EYPT had $2,117K increase in cash & cash equivalents over the period. -$243,390K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues | 31,371 |
| Duravyu direct research and development expense | 149,293 |
| Other direct research and development expense | 3,036 |
| Personnel expense (including stock based compensation) | 83,471 |
| Facilities expense | 6,638 |
| Depreciation and amortization | 2,309 |
| Intellectual property expense | 898 |
| Legal, corporate and professional expenses | 12,916 |
| Provision for income taxes | 279 |
| Interest and other income, net | 11,751 |
| Other segment expenses | 16,244 |
| Net loss | -231,962 |
| Depreciation of property and equipment | 2,309 |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | -4,828 |
| Stock-based compensation | 27,873 |
| Deferred income tax | 279 |
| Accounts receivable and other current assets | 10,667 |
| Other assets | 113 |
| Inventory | -492 |
| Accounts payable and accrued expenses | 4,677 |
| Right-of-use assets and operating lease liabilities | 500 |
| Deferred revenue | -28,637 |
| Other noncurrent liabilities | -33 |
| Net cash (used in) provided by operating activities | -240,110 |
| Purchases of marketable securities | 252,020 |
| Sales and maturities of marketable securities | 323,725 |
| Purchases of property and equipment | 3,280 |
| Proceeds from sale of property and equipment | 155 |
| Net cash (used in) provided by investing activities | 68,580 |
| Proceeds from issuance of stock | 173,445 |
| Payment of equity issue costs | 543 |
| Net settlement of stock units to satisfy statutory tax withholding | 1,388 |
| Proceeds from exercise of stock options and employee stock purchase plan | 2,238 |
| Principal payments on finance lease obligations | 105 |
| Net cash (used in) provided by financing activities | 173,647 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 2,117 |
| Cash, cash equivalents and restricted cash at beginning of period | 99,854 |
| Cash, cash equivalents and restricted cash at end of period | 101,971 |
EyePoint, Inc. (EYPT)
EyePoint, Inc. (EYPT)